One bolus dose of gentamicin and early oral therapy versus cefotaxime and subsequent oral therapy in the treatment of febrile urinary tract infection
The efficacy and safety of two different regimens for parenteral treatment of presumed severe febrile urinary tract infection were compared in a randomized study. One hundred fifty-eight patients were treated with either cefotaxime 2 g i.v. twice daily for at least two days followed by norfloxacin 4...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical microbiology & infectious diseases 1997-06, Vol.16 (6), p.455-458 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 458 |
|---|---|
| container_issue | 6 |
| container_start_page | 455 |
| container_title | European journal of clinical microbiology & infectious diseases |
| container_volume | 16 |
| creator | SUNDMAN, K AMEBORN, P BLAD, L SJÖBERG, L VIKERFORS, T |
| description | The efficacy and safety of two different regimens for parenteral treatment of presumed severe febrile urinary tract infection were compared in a randomized study. One hundred fifty-eight patients were treated with either cefotaxime 2 g i.v. twice daily for at least two days followed by norfloxacin 400 mg twice daily orally or one bolus dose of gentamicin 3 mg/kg i.v. and norfloxacin from the start. Three patients randomized to cefotaxime died. Of the 101 patients with verified urinary tract infection, clinical response to assigned therapy was seen in 79% and 74%, respectively. There was no difference in fever duration between the two regimens. The results indicate that one bolus dose of gentamicin with early oral therapy is a safe and effective alternative to common parenteral regimens for empirical treatment of febrile urinary tract infection. |
| doi_str_mv | 10.1007/BF02471910 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_16253317</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16253317</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-c7fad80558f83426c4dd23513457c25742d50fba402e2a8d15ddb89755a34c5d3</originalsourceid><addsrcrecordid>eNpd0c9rFTEQB_AgSn2tXrwLQcSDsJqfm92jFqtCoRc9L7PJRFN2k2eSLb4_xP_X2D4qekrg-5lhhiHkGWdvOGPm7fsLJpThI2cPyI4rqTsljXxIdmyUqhuNkI_JaSnXrOHBmBNyMgo1GDXuyK-riHROy1aoSwVp8vQbxgprsCFSiI4i5OVAU4aF1u-YYX-gN5hLK7DoU4WfYcVbWLa54I-tVf-rW5_2pTUj1PU29dTjnMOCdMshQj60EGxt0qOtIcUn5JGHpeDT43tGvl58-HL-qbu8-vj5_N1lZ2U_1s4aD25gWg9-kEr0VjknpOZSaWOFNko4zfwMigkUMDiunZuH0WgNUlnt5Bl5ddd3n1ObvNRpDcXiskDEtJWJ90JLyU2DL_6D12nLsc029VwMhhnVN_T6DtmcSsnop30Oa1tv4mz6c6jp76Eafn7suM0runt6vEzLXx5zKBYWnyHaUO6ZMIKNg5a_ASwQm_8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>612870746</pqid></control><display><type>article</type><title>One bolus dose of gentamicin and early oral therapy versus cefotaxime and subsequent oral therapy in the treatment of febrile urinary tract infection</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>SUNDMAN, K ; AMEBORN, P ; BLAD, L ; SJÖBERG, L ; VIKERFORS, T</creator><creatorcontrib>SUNDMAN, K ; AMEBORN, P ; BLAD, L ; SJÖBERG, L ; VIKERFORS, T</creatorcontrib><description>The efficacy and safety of two different regimens for parenteral treatment of presumed severe febrile urinary tract infection were compared in a randomized study. One hundred fifty-eight patients were treated with either cefotaxime 2 g i.v. twice daily for at least two days followed by norfloxacin 400 mg twice daily orally or one bolus dose of gentamicin 3 mg/kg i.v. and norfloxacin from the start. Three patients randomized to cefotaxime died. Of the 101 patients with verified urinary tract infection, clinical response to assigned therapy was seen in 79% and 74%, respectively. There was no difference in fever duration between the two regimens. The results indicate that one bolus dose of gentamicin with early oral therapy is a safe and effective alternative to common parenteral regimens for empirical treatment of febrile urinary tract infection.</description><identifier>ISSN: 0934-9723</identifier><identifier>EISSN: 1435-4373</identifier><identifier>DOI: 10.1007/BF02471910</identifier><identifier>PMID: 9248749</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Bacterial diseases ; Bacterial diseases of the urinary system ; Biological and medical sciences ; Cefotaxime - adverse effects ; Cefotaxime - therapeutic use ; Drug Therapy, Combination - adverse effects ; Drug Therapy, Combination - therapeutic use ; Female ; Fever - drug therapy ; Gentamicins - adverse effects ; Gentamicins - therapeutic use ; Human bacterial diseases ; Humans ; Infections ; Infectious diseases ; Male ; Medical sciences ; Middle Aged ; Norfloxacin - adverse effects ; Norfloxacin - therapeutic use ; Prospective Studies ; Urinary Tract Infections - drug therapy</subject><ispartof>European journal of clinical microbiology & infectious diseases, 1997-06, Vol.16 (6), p.455-458</ispartof><rights>1997 INIST-CNRS</rights><rights>MMV Medizin Verlag GmbH 1997</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c369t-c7fad80558f83426c4dd23513457c25742d50fba402e2a8d15ddb89755a34c5d3</citedby><cites>FETCH-LOGICAL-c369t-c7fad80558f83426c4dd23513457c25742d50fba402e2a8d15ddb89755a34c5d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2720985$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9248749$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SUNDMAN, K</creatorcontrib><creatorcontrib>AMEBORN, P</creatorcontrib><creatorcontrib>BLAD, L</creatorcontrib><creatorcontrib>SJÖBERG, L</creatorcontrib><creatorcontrib>VIKERFORS, T</creatorcontrib><title>One bolus dose of gentamicin and early oral therapy versus cefotaxime and subsequent oral therapy in the treatment of febrile urinary tract infection</title><title>European journal of clinical microbiology & infectious diseases</title><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><description>The efficacy and safety of two different regimens for parenteral treatment of presumed severe febrile urinary tract infection were compared in a randomized study. One hundred fifty-eight patients were treated with either cefotaxime 2 g i.v. twice daily for at least two days followed by norfloxacin 400 mg twice daily orally or one bolus dose of gentamicin 3 mg/kg i.v. and norfloxacin from the start. Three patients randomized to cefotaxime died. Of the 101 patients with verified urinary tract infection, clinical response to assigned therapy was seen in 79% and 74%, respectively. There was no difference in fever duration between the two regimens. The results indicate that one bolus dose of gentamicin with early oral therapy is a safe and effective alternative to common parenteral regimens for empirical treatment of febrile urinary tract infection.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Bacterial diseases</subject><subject>Bacterial diseases of the urinary system</subject><subject>Biological and medical sciences</subject><subject>Cefotaxime - adverse effects</subject><subject>Cefotaxime - therapeutic use</subject><subject>Drug Therapy, Combination - adverse effects</subject><subject>Drug Therapy, Combination - therapeutic use</subject><subject>Female</subject><subject>Fever - drug therapy</subject><subject>Gentamicins - adverse effects</subject><subject>Gentamicins - therapeutic use</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Norfloxacin - adverse effects</subject><subject>Norfloxacin - therapeutic use</subject><subject>Prospective Studies</subject><subject>Urinary Tract Infections - drug therapy</subject><issn>0934-9723</issn><issn>1435-4373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpd0c9rFTEQB_AgSn2tXrwLQcSDsJqfm92jFqtCoRc9L7PJRFN2k2eSLb4_xP_X2D4qekrg-5lhhiHkGWdvOGPm7fsLJpThI2cPyI4rqTsljXxIdmyUqhuNkI_JaSnXrOHBmBNyMgo1GDXuyK-riHROy1aoSwVp8vQbxgprsCFSiI4i5OVAU4aF1u-YYX-gN5hLK7DoU4WfYcVbWLa54I-tVf-rW5_2pTUj1PU29dTjnMOCdMshQj60EGxt0qOtIcUn5JGHpeDT43tGvl58-HL-qbu8-vj5_N1lZ2U_1s4aD25gWg9-kEr0VjknpOZSaWOFNko4zfwMigkUMDiunZuH0WgNUlnt5Bl5ddd3n1ObvNRpDcXiskDEtJWJ90JLyU2DL_6D12nLsc029VwMhhnVN_T6DtmcSsnop30Oa1tv4mz6c6jp76Eafn7suM0runt6vEzLXx5zKBYWnyHaUO6ZMIKNg5a_ASwQm_8</recordid><startdate>19970601</startdate><enddate>19970601</enddate><creator>SUNDMAN, K</creator><creator>AMEBORN, P</creator><creator>BLAD, L</creator><creator>SJÖBERG, L</creator><creator>VIKERFORS, T</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>19970601</creationdate><title>One bolus dose of gentamicin and early oral therapy versus cefotaxime and subsequent oral therapy in the treatment of febrile urinary tract infection</title><author>SUNDMAN, K ; AMEBORN, P ; BLAD, L ; SJÖBERG, L ; VIKERFORS, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-c7fad80558f83426c4dd23513457c25742d50fba402e2a8d15ddb89755a34c5d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Bacterial diseases</topic><topic>Bacterial diseases of the urinary system</topic><topic>Biological and medical sciences</topic><topic>Cefotaxime - adverse effects</topic><topic>Cefotaxime - therapeutic use</topic><topic>Drug Therapy, Combination - adverse effects</topic><topic>Drug Therapy, Combination - therapeutic use</topic><topic>Female</topic><topic>Fever - drug therapy</topic><topic>Gentamicins - adverse effects</topic><topic>Gentamicins - therapeutic use</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Norfloxacin - adverse effects</topic><topic>Norfloxacin - therapeutic use</topic><topic>Prospective Studies</topic><topic>Urinary Tract Infections - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SUNDMAN, K</creatorcontrib><creatorcontrib>AMEBORN, P</creatorcontrib><creatorcontrib>BLAD, L</creatorcontrib><creatorcontrib>SJÖBERG, L</creatorcontrib><creatorcontrib>VIKERFORS, T</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>European journal of clinical microbiology & infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SUNDMAN, K</au><au>AMEBORN, P</au><au>BLAD, L</au><au>SJÖBERG, L</au><au>VIKERFORS, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>One bolus dose of gentamicin and early oral therapy versus cefotaxime and subsequent oral therapy in the treatment of febrile urinary tract infection</atitle><jtitle>European journal of clinical microbiology & infectious diseases</jtitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><date>1997-06-01</date><risdate>1997</risdate><volume>16</volume><issue>6</issue><spage>455</spage><epage>458</epage><pages>455-458</pages><issn>0934-9723</issn><eissn>1435-4373</eissn><abstract>The efficacy and safety of two different regimens for parenteral treatment of presumed severe febrile urinary tract infection were compared in a randomized study. One hundred fifty-eight patients were treated with either cefotaxime 2 g i.v. twice daily for at least two days followed by norfloxacin 400 mg twice daily orally or one bolus dose of gentamicin 3 mg/kg i.v. and norfloxacin from the start. Three patients randomized to cefotaxime died. Of the 101 patients with verified urinary tract infection, clinical response to assigned therapy was seen in 79% and 74%, respectively. There was no difference in fever duration between the two regimens. The results indicate that one bolus dose of gentamicin with early oral therapy is a safe and effective alternative to common parenteral regimens for empirical treatment of febrile urinary tract infection.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>9248749</pmid><doi>10.1007/BF02471910</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0934-9723 |
| ispartof | European journal of clinical microbiology & infectious diseases, 1997-06, Vol.16 (6), p.455-458 |
| issn | 0934-9723 1435-4373 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_16253317 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Aged, 80 and over Bacterial diseases Bacterial diseases of the urinary system Biological and medical sciences Cefotaxime - adverse effects Cefotaxime - therapeutic use Drug Therapy, Combination - adverse effects Drug Therapy, Combination - therapeutic use Female Fever - drug therapy Gentamicins - adverse effects Gentamicins - therapeutic use Human bacterial diseases Humans Infections Infectious diseases Male Medical sciences Middle Aged Norfloxacin - adverse effects Norfloxacin - therapeutic use Prospective Studies Urinary Tract Infections - drug therapy |
| title | One bolus dose of gentamicin and early oral therapy versus cefotaxime and subsequent oral therapy in the treatment of febrile urinary tract infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T17%3A52%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=One%20bolus%20dose%20of%20gentamicin%20and%20early%20oral%20therapy%20versus%20cefotaxime%20and%20subsequent%20oral%20therapy%20in%20the%20treatment%20of%20febrile%20urinary%20tract%20infection&rft.jtitle=European%20journal%20of%20clinical%20microbiology%20&%20infectious%20diseases&rft.au=SUNDMAN,%20K&rft.date=1997-06-01&rft.volume=16&rft.issue=6&rft.spage=455&rft.epage=458&rft.pages=455-458&rft.issn=0934-9723&rft.eissn=1435-4373&rft_id=info:doi/10.1007/BF02471910&rft_dat=%3Cproquest_cross%3E16253317%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=612870746&rft_id=info:pmid/9248749&rfr_iscdi=true |